Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Yee

Showing results (51-60 of 97) with videos related to

Pageof 10
Sort By:
Blood Cancer Journal|November 1, 2022
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myelomaKevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, et al.
Blood Advances|June 25, 2025
Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapyJessica S Little, Angelica Medina Pena, E Bridget Kim, et al.
British Journal of Haematology|February 25, 2015
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell deathYuko Mishima, Loredana Santo, Homare Eda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2014
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapyChirayu G Patel, Andrew J Yee, Tyler A Scullen, et al.
Blood|March 30, 2016
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myelomaNikoletta Lendvai, Andrew J Yee, Ioanna Tsakos, et al.
Blood Cancer Journal|December 23, 2024
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myelomaRie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2019
Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body <sup>18</sup>F-Florbetapir PET/CTEric C Ehman, M Samir El-Sady, Marie F Kijewski, et al.
JACC. Heart Failure|September 7, 2024
Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and OutcomesOlivier F Clerc, Shilpa Vijayakumar, Sarah A M Cuddy, et al.
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
JACC. Cardiovascular Imaging|September 12, 2025
Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell TherapyDominik C Benz, Olivier F Clerc, Sarah A M Cuddy, et al.
Pageof 10

Showing results (51-60 of 97) with videos related to

Sort By:
Pageof 10
Blood Cancer Journal|November 1, 2022
Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myelomaKevin Charles Miller, Patrick Connor Johnson, Jeremy S Abramson, et al.
Blood Advances|June 25, 2025
Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapyJessica S Little, Angelica Medina Pena, E Bridget Kim, et al.
British Journal of Haematology|February 25, 2015
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell deathYuko Mishima, Loredana Santo, Homare Eda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2014
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapyChirayu G Patel, Andrew J Yee, Tyler A Scullen, et al.
Blood|March 30, 2016
Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myelomaNikoletta Lendvai, Andrew J Yee, Ioanna Tsakos, et al.
Blood Cancer Journal|December 23, 2024
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myelomaRie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 8, 2019
Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body <sup>18</sup>F-Florbetapir PET/CTEric C Ehman, M Samir El-Sady, Marie F Kijewski, et al.
JACC. Heart Failure|September 7, 2024
Functional Status and Quality of Life in Light-Chain Amyloidosis: Advanced Imaging, Longitudinal Changes, and OutcomesOlivier F Clerc, Shilpa Vijayakumar, Sarah A M Cuddy, et al.
JCO Precision Oncology|September 11, 2020
Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET StudyNoopur Raje, Ian Chau, David M Hyman, et al.
JACC. Cardiovascular Imaging|September 12, 2025
Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell TherapyDominik C Benz, Olivier F Clerc, Sarah A M Cuddy, et al.
Pageof 10